Kallmann Syndrome
17
2
4
8
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
11.8%
2 terminated out of 17 trials
80.0%
-6.5% vs benchmark
18%
3 trials in Phase 3/4
13%
1 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (17)
The Molecular Basis of Inherited Reproductive Disorders
Patient and Healthcare Professional Views on Genetic/Genomic Information and Testing
Kisspeptin Administration in the Adult
Kisspeptin in the Evaluation of Delayed Puberty
GROWing Up With Rare GENEtic Syndromes
Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)
Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders
Genetics of Reproductive Disorders (Including Kallmann Syndrome) and Cleft Lip and/or Palate
Efficacy and Safety of Long Term Use of hCG or hCG Plus hMG in Males With Isolated Hypogonadotropic Hypogonadism (IHH)
Health Needs of Patients With Kallmann Syndrome
Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With Hypogonadism
Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism (IHH)
Human Menopausal Gonadotropin Combining With Human Chorionic Gonadotropin Treat Congenital Hypogonadotropic Hypogonadism
Investigating the Regulation of Reproductive Hormones in Adult Men
Sequential Therapy for Hypogonadotropic Hypogonadism
A Study to Characterize Epidemiology, Clinical and Genetic Features of Kallmann Syndrome in Finland